Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy Daiichi Sankyo and AstraZeneca announced that Datroway has been approved in the EU as […]
Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease Novartis announced that the U.S. FDA has approved Pluvicto in combination with […]
Weekly Digest – August 2026 Weekly Digest – August 2026 04 August 2026: U.S. Food and Drug Administration grants Breakthrough Therapy Designation to Multitude Therapeutics’ AMT-253 Multitude Therapeutics announced that the U.S. FDA has granted Breakthrough Therapy Designation to AMT-253, […]
Weekly Digest – August 2026 Weekly Digest – August 2026 05 August 2026: Multitude Therapeutics’ AMT-676 receives Breakthrough Therapy Designation from China’s CDE Multitude Therapeutics’ CDH17-targeted ADC AMT-676 has been granted Breakthrough Therapy Designation by China’s CDE for the treatment […]
Weekly Digest – August 2026 Weekly Digest – August 2026 03 August 2026: TQB2102 receives BTD from the CDE for patients with unresectable or metastatic HER2-low Breast cancer Sino Biopharmaceutical’s next-generation HER2 bispecific ADC TQB2102 has received its third Breakthrough […]
Weekly Digest – August 2026 Weekly Digest – August 2026 03 August 2026: U.S. FDA grants Orphan Drug Designation to Zai Lab’s DLL3-targeting ADC Zocilurtatug pelitecan for the treatment of Neuroendocrine Carcinomas Zai Lab’s DLL3-targeting ADC Zocilurtatug pelitecan has received […]
Weekly Digest – July 2026 Weekly Digest – July 2026 28 July 2026: AstraZeneca receives CDSCO approval for Enhertu followed by THP for adults with HER2-positive stage II or III early Breast cancer AstraZeneca Pharma India announced that the Central […]
Weekly Digest – July 2026 Weekly Digest – July 2026 29 July 2026: AbbVie announces availability of ELAHERE in Singapore for the treatment of platinum-resistant Ovarian cancer AbbVie announced the availability of ELAHERE, the first folate receptor alpha-targeted antibody-drug conjugate, […]
Weekly Digest – July 2026 Weekly Digest – July 2026 29 July 2026: ImmunityBio receives UAE Marketing Authorization for ANKTIVA in BCG-unresponsive NMIBC (CIS and papillary disease) and mNSCLC ImmunityBio announced that the United Arab Emirates has granted marketing authorization […]
Weekly Digest – July 2026 Weekly Digest – July 2026 28 July 2026: DualityBio and BioNTech’s B7-H3 ADC DB-1311 granted China NMPA BTD for metastatic castration-resistant Prostate cancer DualityBio and BioNTech announced that China’s NMPA has granted Breakthrough Therapy Designation […]
